Myeloid infection links epithelial and B cell tropisms of murid herpesvirus-4. by Frederico, Bruno et al.
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Abstract 
 Gamma-herpesviruses persist in lymphocytes and cause disease by 
driving their proliferation. Lymphocyte infection is therefore a key 
pathogenetic event. Murid Herpesvirus-4 (MuHV-4) is a rhadinovirus that 
like the related Kaposi's Sarcoma-associated Herpesvirus persists in B 
cells in vivo yet infects them poorly in vitro. Here we used MuHV-4 to 
understand how virion tropism sets the path to lymphocyte colonization. 
Virions that were highly infectious in vivo showed a severe post-binding 
block to B cell infection. Host entry was accordingly an epithelial infection 
and B cell infection a secondary event. Macrophage infection by cell-free 
virions was also poor, but improved markedly when virion binding 
improved or when macrophages were co-cultured with infected 
fibroblasts. Under the same conditions B cell infection remained poor; it 
improved only when virions came from macrophages. This reflected better 
cell penetration and correlated with antigenic changes in the virion fusion 
complex. Macrophages were seen to contact acutely infected epithelial 
cells, and cre / lox-based virus tagging showed that almost all the virus 
recovered from lymphoid tissue had passed through lysM+ and CD11c+ 
myeloid cells. Thus MuHV-4 reached B cells in 3 distinct stages: incoming 
virions infected epithelial cells; infection then passed to myeloid cells; 
glycoprotein changes then allowed B cell infection. These data identify 
new complexity in rhadinovirus infection and potentially also new 
vulnerability to intervention. 
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Author Summary 
 Rhadinoviruses cause lymphocytic cancers. Their infection of 
lymphocytes is therefore an important therapeutic target. How this occurs is 
unclear. One prevalent hypothesis has been that virions directly infect 
lymphocytes when they enter new hosts. Here we show that host entry by Murid 
Herpesvirus-4, a close relative of the Kaposi's Sarcoma-associated Herpesvirus, 
is an epithelial rather than a lymphocyte infection: the mucosal lymphoid 
colonization typical of acute infectious mononucleosis only occurred later. 
Macrophages were closely associated with the acutely infected epithelium, and 
most if not all of the virus reaching B cells showed evidence of previous myeloid 
cell infection. Macrophage-derived virions showed a greatly enhanced capacity 
for lymphocyte infection that was associated with antigenic changes in the viral 
fusion proteins. Thus host colonization required epithelial and myeloid 
infections before there was lymphocyte infection. The implication is that each of 
these infection events could be independently targeted to limit viral persistence. 
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Introduction 
 Herpesviruses are among the most prevalent of all persistent 
pathogens. Thus even when disease is individually rare, the total burden in 
populations is large. The difficulty of eliminating latent viral genomes 
makes latency establishment an important target for infection control. 
Gamma-herpesviruses persist in lymphocytes. Epstein-Barr virus (EBV) 
infects B cells better than epithelial cells in vitro, and prominently 
colonizes tonsillar B cells during acute infectious mononucleosis [1]. Thus 
EBV [2] and the Kaposi's Sarcoma-associated Herpesvirus (KSHV) [3] have 
been proposed to infect tonsillar B cells directly after oral host entry. 
However infectious mononucleosis post-dates EBV host entry by at least a 
month [4]. Therefore the infection seen at that time may correspond to 
host exit rather than entry, and vaccination to prevent B cell infection 
failed to reduce EBV seroconversion rates [5]. 
 One barrier to understanding gamma-herpesviruses solely through 
EBV and KSHV is that their narrow species tropisms limit in vivo analysis. 
Experimentally accessible gamma-herpesviruses such as Murid 
Herpesvirus-4 (MuHV-4) [6-9] consequently provide an important source 
of information. MuHV-4 is closely related to KSHV [10, 11]. Like EBV and 
KSHV it persists in B cells [12]. It also infects myeloid cells [13]. Most 
experimental infections have delivered MuHV-4 intranasally to mice under 
general anesthesia; aspirated virions then infect lung epithelial cells [14]. 
The detection by PCR of replication-deficient viral DNA from flow 
 5 
cytometrically sorted lung B cells in this setting led to the idea that B cells 
are a direct infection target [15, 16]. However viral DNA+ B cells were not 
detected in lymphoid organs, and adsorbed inoculum debris was not 
excluded as the source of viral DNA. A further caveat to drawing general 
conclusions from lung infection is that MuHV-4 inhaled without anesthesia 
does not reach this site: it replicates just in the nose [17] before following 
a CD11c-dependent route to lymphoid tissue [18]. 
 Our understanding of human herpesvirus infections is based largely 
on analysis in vitro. A key task with MuHV-4 is therefore to relate in vitro 
tropisms to host colonization. Fibroblast-propagated MuHV-4 efficiently 
infects mice [17, 19] yet like KSHV seems to infect B cells poorly: despite 
reports of MuHV-4 infected B cell lines [20, 21] and phenotypic changes in 
virus-exposed B cells [22, 23], efficient B cell infection has not been 
demonstrated. MuHV-4 depends on heparan sulfate (HS) to infect 
adherent cells [24], and poor B cell infection by MuHV-4 and KSHV has 
been attributed to B cells lacking HS [25]. However infection was not 
convincingly demonstrated even when B cell HS expression increased. 
Therefore the barriers to B cell infection remain ill-defined. 
 Here we found no evidence for direct mucosal B cell infection by 
MuHV-4 entering the upper respiratory tract. Host entry was instead an 
epithelial infection. This corresponded to in vitro B cell infection showing 
binding and post-binding blocks. Unlike B cell infection, myeloid infection 
was limited only by binding and worked well by co-culture with infected 
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fibroblasts. B cell infection improved only when virions came from 
myeloid cells. These virions showed a constitutive triggering of entry-
associated changes in gB and gH. Myeloid cells were closely associated 
with the acutely infected epithelium, and cre / lox virus marking showed 
that most of the virus reaching lymphoid tissue had passed through cells 
expressing CD11c and myeloid-specific lysozyme (lysM). Thus we propose 
that rhadinoviruses entering new hosts infect epithelial cells, then myeloid 
cells, and only then B cells. 
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Results 
MuHV-4 infects the nasal-associated lymphoid tissue only as a 
secondary event in host colonization 
 Oral MuHV-4 is non-infectious, and its natural entry route appears 
to be the upper respiratory tract [17]. The murine nasal-associated 
lymphoid tissue (NALT) is analogous to human tonsils [26] and provides a 
potential target for lymphotropic viruses entering the nasopharynx. To 
determine whether MuHV-4 targets the NALT, we allowed unanesthetized 
mice to inhale virus and visualized infection 6 days later by 
immunostaining with a polyclonal, MuHV-4-specific rabbit serum (Fig.1a-
c). Lytic antigens were abundant in the olfactory neuroepithelium (Fig.1a) 
but absent from the NALT and its overlying epithelium (Fig.1b). Most of 
the neuroepithelium is anterior to the NALT, and so potentially more 
accessible, but even when neuroepithelial infection was evident in the 
same histological section (Fig.1c) the NALT lacked viral antigens. 
 Our immune serum recognizes predominantly MuHV-4 lytic 
antigens [27], so it remained possible that the NALT was latently infected. 
We tested this by in situ hybridization for the viral tRNA/miRNAs that are 
abundantly expressed in latently infected splenic B cells [28]. Again 
neuroepithelial infection was readily identifiable (Fig.1d) but NALT 
infection was not (Fig.1e), even when neuroepithelial cells in the same 
histological section were tRNA/miRNA+ (Fig.1f). At 14 days post-infection 
viral tRNA/miRNA expression was abundant in the NALT (Fig.1g). 
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However this is after the virus spread and amplification associated with 
infectious mononucleosis [7], and infection was accordingly abundant also 
in lymph nodes and the spleen (Fig.1g). Thus the primary i.n. infection was 
epithelial, and NALT infection did not occur until there was evidence of 
systemic virus spread. 
 
Detecting B cell infection by eGFP expression 
 To understand why the NALT was not acutely infected we tested 
virions for their capacity to infect B cells. A key point was to reliably 
identify B cell infection. Viral tRNA/miRNA detection is not easily 
combined with staining for cell type-specific markers, and while some 
infected B cells express ORF73 and M2 [29], little ORF73 seems to be made 
[30] and M2 expression is unlikely to be universal. We therefore used an 
intergenic EF1 promoter to express constitutively viral eGFP (Fig.S1). 
Mice infected with this virus showed eGFP expression in 1.7% of CD19+ 
lymph node B cells, consistent with PCR-based estimates of wild-type virus 
loads [29, 31, 32]; and it labelled more convincingly than did the BAC-
associated HCMV IE1-eGFP cassette A20 B cells made more susceptible to 
MuHV-4 infection by over-expression of the HS carrier syndecan-1. It 
therefore provided a good basis for detecting B cell infection. 
 
B cell infection remains poor regardless of virion HS dependence 
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 We next used EF1-eGFP+ MuHV-4 to compare the infectibility of 
different cell types. For consistency with studies using other read-outs [20, 
21, 24, 33] we used CHO-K1 epithelial cells, RAW-264 myeloid cells, and 
NS0 and A20 B cells. We exposed each to cell-free virions and assayed 
infection 18h later by flow cytometry (Fig.2). A particular question was 
how far cellular HS expression limits infection. MuHV-4 HS dependence is 
due in part to the inhibitory effect of its gp150, as gp150 null mutants are 
much less HS-dependent in binding and infection than the wild-type [24]. 
We therefore compared infection by gp150+EF1-eGFP+ and gp150-EF1-
eGFP+ virions. 
 Gp150- and gp150+ MuHV-4 infected HS+ CHO epithelial cells 
similarly. Gp150- virions infected HS- CHO cells much better - 
approximately 30-fold fewer virions than wild-type gave an equivalent 
number of eGFP+ cells (Fig.2a, 2b). Gp150- virions also infected RAW-264 
monocytes better (Fig.2c), arguing that poor HS expression limits myeloid 
infection. In contrast, both gp150- and gp150+ virions infected A20 B cells 
poorly (<1% eGFP+ at 10 p.f.u. / cell). The B cell lines WEHI-231 and BCL-1 
also showed <1% eGFP expression after exposure (10 p.f.u. / cell, 18h) to 
gp150+EF1-eGFP+ or gp150-EF1-eGFP+ virions (data not shown). 
Therefore poor B cell infection could not be explained simply by a lack of 
HS. NS0 myeloma cells were infected better than A20, WEHI-231 or BCL-1, 
particularly by gp150- virions, but remained less infectible than RAW-264 
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or HS- CHO cells. Therefore all B cell-derived lines showed an infection 
block beyond poor HS expression. 
 
HS expression by different cell types 
 We used flow cytometry to quantitate cellular HS display (Fig.3). 
MAb F58-10E4 recognizes a sulfation-dependent epitope [34], while mAb 
NAH46 recognizes a sulfation-independent epitope [35]. Both recognize 
most forms of HS because it typically shows partial sulfation [36]. Neither 
mAb stained HS- CHO cells, nor showed more than minimal staining of 
RAW-264 and A20 cells. NAH46 strongly stained HS+ CHO cells and NS0 
cells, whereas F58-10E4 stained HS+ CHO cells strongly and NS0 cells only 
weakly. Thus CHO cells expressed partially sulfated HS; NS0 cells 
expressed largely unsulfated heparan; and A20 and RAW-264 cells 
expressed little of either form. 
What HS forms MuHV-4 binds are unknown. Therefore to measure 
functionally relevant HS display we stained cells with an Fc fusion of the 
viral gp70 HS binding domains (gp70-SCR1-3-Fc) [33] (Fig.3). An Fc fusion 
of the MuHV-4 gp150 residues 1-250, which does not detectably bind to 
cells [37], provided a negative control. Gp70-SCR1-3-Fc binding was more 
sensitive than mAb binding, possibly because it binds to a wider range of 
HS modifications, but like mAb NAH46 it bound HS+ CHO and NS0 cells 
well, RAW-264 and A20 cells less well, and HS- CHO cells hardly at all. Thus 
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NS0 cells were infected poorly despite displaying heparan suitable for 
virus binding. 
 
HS interactions determine virion binding but not infection 
We next tested cell binding by virions, using gp150+ and gp150- 
versions of MuHV-4 made fluorescent by an eGFP tag on the abundant 
envelope component gM [38] (Fig.4). Gp150-gM-eGFP+ virions bound 
better than gp150+gM-eGFP+ to all cell types, but the difference was most 
marked for HS- CHO cells, A20 B cells and RAW-264 monocytes. Thus 
gp150+ virion binding correlated with cellular HS display, and gp150- 
virion binding was strong regardless. Both gp150- and gp150+ virions 
bound well to NS0 cells. Comparing Fig.2 with Fig.4 shows that MuHV-4 
infected RAW-264 and HS- CHO cells better than NS0 despite binding 
better to NS0 cells, and that gp150- virions infected A20 cells poorly 
despite binding relatively well. These data therefore supported the idea of 
a post-binding block to B cell infection. 
That gp150- virions bound better than gp150+ to HS+ CHO cells 
(Fig.4) but did not infect them better (Fig.2) suggested that when cell 
binding was very strong, down-stream events could also limit epithelial 
infection. However they limited A20 cell infection even when HS 
expression (Fig.3) and virion binding (Fig.4) were weak. By comparison, 
HS- CHO cells and RAW-264 cells showed a good correlation between 
better gp150- virion binding and better infection. Therefore a post-binding 
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restriction of infection was possible for all cells, but was much more 
severe for B cells. 
 
HS up-regulation confirms that B cell infection is blocked post-
binding  
 We tested further the relationship between cellular HS expression 
and MuHV-4 infection by expressing in RAW-264 and A20 cells an 
uncleavable form of the HS carrier syndecan-1 (SDC-1) (Fig.5). This 
increased gp150- as well as gp150+ virion binding, presumably because 
gp70 and gH/gL attach virions better than does just the HS-independent 
binding regulated by gp150. Gp70-SCR1-3-Fc bound only marginally 
better to RAW-264-SDC-1 cells than to RAW-264 (Fig.5a), but virion 
binding (Fig.5b) and infection (Fig.5c) both increased. By contrast, both 
gp70-SCR1-3-Fc (Fig.5a) and virions (Fig.5b) bound substantially better to 
A20-SDC-1 cells than to A20, but infection remained negligible (Fig.5c). 
Therefore again there was a post-binding block to B cell infection. 
 
Co-culture with infected fibroblasts improves myeloid infection but 
not B cell infection 
 Probably most in vivo herpesvirus spread occurs through cell / cell 
contact rather than cell-free virion release [39]; MuHV-4 lacking gp150 
accordingly spreads normally in vivo despite poor virion release [27], 
whereas MuHV-4 lacking gp48, which is impaired in cell / cell spread, is 
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attenuated [40]. Thus as B cells were infected down-stream of host entry 
(Fig.1), we reasoned that it might involve cell / cell contact rather than 
cell-free virions. However A20 B cells co-cultured overnight 1:1 with 
infected BHK-21 cells (1 p.f.u. / cell gp150+EF1-eGFP+ or gp150-EF1-
eGFP+ virus, 24h) remained <1% eGFP+ (0.10 ± 0.02% eGFP+ for gp150+ 
and 0.31 ± 0.04% eGFP+ for gp150-) (mean ± SD of triplicate cultures). By 
contrast RAW-264 monocytes co-cultured with infected BHK-21 cells 
became 40-60% eGFP+ (Fig.6a). RAW-264 cells were infected 
approximately 30-fold better by cell-free gp150- virions than by gp150+ 
(Fig.2a). Co-cultures showed only a 3-fold difference, presumably because 
cell / cell contact made virion binding less HS-dependent. Therefore direct 
contact with infected fibroblasts allowed efficient myeloid infection. The 
contrasting failure to improve B cell infection in the same way was 
consistent with this having an additional, post-binding block that required 
a different solution. 
 
B cell infection via myeloid cells 
 That MuHV-4 targets CD11c+ cells in lymph nodes [18] suggested 
that myeloid infection might make MuHV-4 B cell-tropic. We therefore 
next co-cultured A20 B cells 1:1 with MuHV-4-exposed RAW-264 
monocytes (3 p.f.u. / cell, 18h). In contrast to the negligible effect of co-
culture with infected BHK-21 cells, this led to 6.15 ± 1.28% of A20 cells 
becoming eGFP+ for gp150+ MuHV-4 and 12.79 ± 2.23% becoming eGFP+ 
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for gp150- (mean ± SD of triplicate cultures). Co-culture with RAW-264 
cells therefore promoted A20 B cell infection. Similar results were 
obtained with splenic B cells (Fig.6b). We could also infect splenic B cells 
by co-culture with MuHV-4-infected peritoneal macrophages (Fig.6c). 
 As a further measure of infection we used a MuHV-4 derivative 
(MuHV-RG) in which cre recombinase switches reporter gene expression 
from mCherry to eGFP (Fig.6d, 6e). Thus MuHV-RG is mCherry+ until it 
infects cre+ cells and becomes eGFP+. The reporter gene is expressed from 
a lytic cycle promoter, but NS0 B cells support viral lytic gene expression 
[13] so we co-cultured cre+ NS0 cells with MuHV-RG-exposed cre- BHK-21 
cells or cre- RAW-264 cells. Co-culture with RAW-264 cells gave more 
eGFP+ NS0 cells than did co-culture with BHK-21 cells (Fig.6f). Therefore 
myeloid infection promoted B cell infection. 
 
Myeloid-derived virions show enhanced B cell penetration 
 Co-culture infections are difficult to dissect, so we tested next 
whether cell-free virions derived from myeloid cells could also infect B 
cells (Fig.7). Gp150+ virions from RAW-264 cells gave greater eGFP 
expression in splenic B cells than did those from BHK-21 cells. RAW-264-
derived gp150- virions worked substantially better (Fig.7a, 7b), indicating 
that without cell / cell contact gp150 significantly inhibited B cell binding. 
Viral DNA quantitation by Q-PCR (Fig.7c) showed more gp150- than 
gp150+ binding to B cells, with little difference between RAW-264 cell-
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derived and BHK-21 cell-derived virions. Infectious centre assays and 
eGFP expression by contrast showed considerably more infection by RAW-
264 cell-derived virions. Therefore virion passage through myeloid cells 
improved B cell penetration rather than B cell binding. 
 
Antigenic changes in myeloid cell-derived virions 
 Immunoblotting showed differences in gB and gp150 between BHK-
21 cell-derived and RAW-264 cell-derived virions (Fig.8a). However these 
seemed unlikely to account for their different tropisms: gB N-terminus 
recognition by mAb MG-2C10, which depends on cell type-specific O-
glycosylation, was reduced for RAW-264 cell-derived virions but deleting 
the gB N-terminus has no obvious effect on B cell colonization [41]; gp150 
migration and recognition, which also vary with O-glycosylation [42], were 
different between BHK-21 and RAW-264 cell-derived virions but gp150 
disruption enhanced B cell binding by both without being sufficient for 
infection (Fig.7). 
 An important feature of virions not revealed by immunoblotting is 
that gB and gH - which drive herpesvirus membrane fusion - change in 
antigenicity during cell entry [43, 44]. The gH of extracellular virions is 
bound to gL and so recognized by gH/gL-specific mAbs; following 
endocytosis gH/gL epitopes are lost and gH-only epitopes retained; upon 
fusion, which occurs in late endosomes, gH-only epitopes are also lost. 
Similarly, the gB of extracellular virions is recognized by mAb BN-1A7 but 
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not mAb MG-1A12; following endocytosis gB gains MG-1A12 recognition; 
and then upon fusion it loses BN-1A7 recognition [45]. Thus virions 
progress from BN-1A7+MG-1A12-gH/gL+gH-onlylo (extracellular) to BN-
1A7+MG-1A12+gH/gL-gH-onlyhi (post-endocytic, but still pre-fusion) to BN-
1A7-MG-1A12+gH/gL-gH-only- (post-fusion). This is illustrated in Fig.8b: 
virions bound to NMuMG cells at 4oC were not recognized by mAb MG-
1A12 (post-endocytic gB) and were poorly recognized by mAb MG-9B10 
(gH-only); after endocytosis, virions started to lose recognition by T2C12 
and BN-1A7, strongly gained recognition by MG-1A12, and showed some 
increase in recognition by MG-9B10. The residual BN-1A7, T2C12 and MG-
9B10 staining after 2h at 37oC was outside LAMP-1+ late endosomes, that 
is on virions that had not yet reached their site of fusion. 
 RAW-264 cell-derived virions constitutively showed the post-
endocytic forms of gB and gH, but not the post-fusion forms (Fig.8c). The 
mAb used here to detect pre-fusion gB - SC-9E8 - behaves exactly as mAb 
BN-1A7 [45], and staining for gL followed the same pattern as gH/gL. Thus 
myeloid-derived virions appeared to penetrate B cells better because they 
were already primed for membrane fusion. 
 
In vivo evidence for virus passage through myeloid cells 
 An important in vivo role for myeloid infection in B cell colonization 
would predict that it occurs early after host entry. We tested this by 
immunostaining acutely infected noses. At 1 day post-infection F4/80+ 
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macrophages contacted viral eGFP+ epithelial cells (Fig.9a), and infected 
macrophages occupied areas of viral lytic gene expression (Fig.9b). 
Therefore myeloid infection immediately followed epithelial infection and 
preceded B cell infection (Fig.1). 
 To identify whether the virus reaching B cells had previously 
replicated in a myeloid cell we gave the MHV-RG floxed reporter virus to 
lysM-cre mice, which express cre recombinase in macrophages, 
granulocytes, and some dendritic cells [46] (Fig.9c). Virus recombination 
rates varied between mice, but at 3 days post-inoculation approximately 
1/3 of the MHV-RG recovered from lysM-cre mouse noses was 
eGFP+mCherry-, indicating prior replication in a myeloid cell. At days 5 and 
8 the mean recombination rate was 1/2. By contrast almost all the virus 
recovered from noses of CD19-cre mice, whch express cre recombinase in 
B cells [47], remained eGFP-mCherry+, consistent with B cells not being a 
primary infection target in the upper respiratory tract, and with myeloid 
infection preceding that of B cells. 
 B cells are the major site of MuHV-4 lymphoid infection [29], and 
virus recovered from the draining lymph nodes (SCLN) of CD19-cre mice 
was 80% eGFP+mCherry- at day 8 and almost 100% eGFP+mCherry- at day 
15. LysM-cre mice again showed individual variation, but on average more 
than half the SCLN virus was eGFP+mCherry-. At day 15 post-infection we 
also assayed CD11c-cre mice, which express cre recombinase 
predominantly in dendritic cells [48]. Virus recovered from their SCLN 
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was >90% eGFP+mCherry-. LysM and CD11c expression show only modest 
overlap [46]. Thus most if not all the virus reaching lymph nodes and 
infecting B cells appeared to have passed through a myeloid cell. 
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Discussion 
 An enduring puzzle with MuHV-4 and KSHV has been that they 
persist in B cells in vivo yet infect them poorly in vitro. For MuHV-4 this is 
despite virions growing to high titers and efficiently infecting mice. We 
identified a binding block to myeloid infection that was overcome by co-
culture, and a post-binding block to B cell infection that was overcome by 
virus propagation in myeloid cells. Better B cell penetration was 
associated with virions displaying a post-endocytic form of the gB/gH 
fusion complex. Consistent with these tropisms, host entry was an 
epithelial infection; myeloid infection immediately followed; lymphoid 
infection occurred only later; and most if not all of the virus recovered 
from lymph nodes showed evidence of previous myeloid infection. Virion 
tropism therefore matched host antigen transport in setting an epithelial 
to myeloid to lymphoid infection cycle. 
 Virus binding also presented a hurdle to B cell infection. This 
increased when B cell HS expression increased. However while plasma cell 
differentiation upregulates B cell HS [49], MuHV-4 persists in memory 
rather than plasma B cells; and while interferon upregulates B cell HS [50] 
it also inhibits MuHV-4 infection. Therefore in vivo B cell binding seems 
unlikely to depend on HS up-regulation. Binding also increased when 
virions lacked gp150, but whether such virions are naturally produced is 
unclear: in contrast to the Bovine Herpesvirus-4 gp180 [51], RT-PCR has 
not demonstrated gp150 truncation by splicing (unpublished data); nor 
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were myeloid cell-derived virions functionally gp150-deficient. The 
relative gp150-independence of B cell infection by co-culture suggested 
that sufficient binding occurs instead through myeloid / B cell contact 
[52]. Myeloid infection in turn probably involves contact with infected 
epithelial cells. Thus a need for HS binding by cell-free virions applies 
mainly to host entry [53], where the target was epithelial. 
 Penetration presented a more severe block to B cell infection. B cell 
penetration by EBV requires its gp42 [54]. MuHV-4 and KSHV lack obvious 
gp42 homologs and no MuHV-4 glycoprotein knockout has specifically 
failed to infect B cells [24, 40, 53, 55-57]. Therefore a B cell-specific 
component to the MuHV-4 fusion complex, while difficult to exclude, 
seems unlikely. Instead B cell-tropic virions showed antigenic changes in 
gB and gH. These corresponded to post-endocytic conformation changes 
that precede epithelial membrane fusion [45]. Thus, if the conformation 
changes are a prerequisite for fusion and are not triggered by B cells, 
virion exit through an endocytic / exocytic compartment of myeloid cells 
would allow B cell infection nonetheless. Simple co-culture with 
macrophages increased B cell infection at least 100-fold; lymphoid 
architecture and myeloid / B cell communication doubtless make the 
process more efficient still in vivo. 
 LysM+ (mainly macrophage) and CD11c+ (mainly dendritic) cells 
may have distinct roles in host colonization. Most in vivo myeloid 
populations are heterogeneous, but classically dendritic cells move from 
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peripheral sites to lymph nodes, whereas macrophages are sessile. Thus 
dendritic cells probably play an important role in virus transport. 
Alternatively, lymphatic virion transport could connect key macrophage 
roles in the periphery, where F4/80+ cells were closely associated with 
epithelial infection, and in lymph nodes, where viral DNA is found in 
CD11b+CD11c- cells [18]. Some macrophages express CD11c [58, 59] and 
some CD11c+ cells express lysM, but the overlap is not extensive and not 
all macrophages express lysM [46], so the high percentages of MHV-RG 
recombination in both CD11c-cre and lysM-cre mice suggested that MuHV-
4 might even infect both macrophages and dendritic cells before reaching 
B cells. 
 The epithelial / myeloid / lymphoid infection pathway of MuHV-4 is 
quite different to the epithelial cell / B cell exchange proposed for EBV 
[60]. Thus despite rhadinoviruses and lymphocryptoviruses colonizing 
similar cell populations, they may do so in different ways. Epithelial and 
fibroblast-derived MuHV-4 are strongly epithelial-tropic - we find little 
difference between epithelial and fibroblast infections [55] - as are NS0 
cell-derived virions (data not shown); even RAW-264 cell-derived MuHV-4 
infected epithelial cells better than B cells. This consistent epithelial 
tropism perhaps reflects a predominant need for epithelial entry in the 
viral lifecycle: new infected B cells can come from lymphoproliferation, but 
each new epithelial infection likely requires new cell binding and 
penetration. EBV may have evolved ways to minimise its need for new 
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epithelial infections. However it does not present clinically until infection 
is well established, so events equivalent to the epithelial and myeloid 
infections of MuHV-4 are rarely studied. The striking parallels between 
MuHV-4 host colonization and normal antigen transport would suggest 
that other lymphotropic viruses follow similar routes. 
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Materials and Methods 
Ethics statement  All animal experiments were approved by the 
University of Cambridge ethical review board and by the UK Home Office 
under the 1986 Animal (Scientific Procedures) Act as Project Licence 
80/2538. 
 
Mice  C57BL/6 (Harlan UK), LysM-cre [46], CD19-cre [47] and 
CD11c-cre mice [48] were housed in the Cambridge University 
Department of Pathology animal unit. LysM-cre mice express cre 
recombinase in monocyte / macrophages and neutrophils in place of 
myeloid-specific lysozyme, CD19-cre mice express cre in B cells, and 
CD11c-cre mice express cre predominantly in dendritic cells. Mice were 
given  MuHV-4 intranasally (i.n.) either in 30l under general anesthesia to 
infect both the upper and lower respiratory tract, or in 5l without 
anesthesia to infect just the upper respiratory tract. 
 
Cells  BHK-21 fibroblasts (American type culture collection CCL-
10), CHO-K1 epithelial cells (CCL-61), the glycosaminoglycan-deficient 
CHO-745 mutant (CRL-2242), NMuMG epithelial cells (CRL-1636), NS0 
myeloma cells, A20 B cells (TIB-208), NIH-3T3 cells (CRL-1658), NIH-3T3-
cre cells [61] 293T cells (CRL-11268), and RAW-264 monocytes (TIB-71) 
were cultured in Dulbecco's Modified Eagle's Medium with 2mM 
glutamine, 100U/ml penicillin, 100mg/ml streptomycin and 10% fetal calf 
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serum. Primary cells were cultured in the same medium supplemented 
with 50mM 2-mercaptoethanol. Peritoneal macrophages were harvested 5 
days after intraperitoneal injection of Brewer's thioglycollate medium 
(Sigma Chemical Co.), by injecting and aspirating post-mortem 10ml of 
Dulbecco's Modified Eagle's Medium. Cells non-adherent to tissue culture 
plates (Nunc) after 2h at 37oC were discarded. The remaining cells were 
routinely >90% CD11bhiCD19- by flow cytometry. Spleens were disrupted 
into single cell suspensions by homogenization in a Griffiths tube. Debris 
was removed by filtration (200m), and erythrocytes and dead cells were 
removed by centrifugation on Ficoll. The cells recovered were typically 
60% B cells CD19+, 25% CD4+ T cells and 15% CD8+ T cells. <1% of the 
recovered cells were macrophages (CD11bhi) or dendritic cells (CD11c+). 
Retroviral transduction of A20 cells with an uncleavable form of the 
syndecan-1 extracellular domain has been described [30]. We used the 
same approach to over-express syndecan-1 in RAW-264 cells, selecting 
transduced cells with Zeocin (Invitrogen). As with NIH-3T3-cre cells, we 
generated NS0-cre cells by transduction with a cre expressing retrovirus 
and selected transduced cells with G418. 
 
Viruses All viruses were generated from a BAC-cloned MuHV-4 
genome [62]. Gp150+ and gp150- versions of MuHV-4 with a C-terminal 
eGFP tag on the abundant virion envelope component gM have been 
described [38], as has the generation of MuHV-4 with an intergenic EF1-
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eGFP expression cassette [63]. We made a gp150- version of the EF1-
eGFP BAC by RecA-mediated recombination of a genomic clone containing 
multiple stop codons at genomic co-ordinate 69743 [24]. This terminated 
the 483 amino acid gp150 coding sequence after 93 amino acids. 
 To make MuHV-4-RG, in which cre recombinase switched reporter 
gene expression from mCherry to eGFP, we started with a derivative of 
pEGFP-C2 (Clontech) in which the eGFP coding sequence had been 
replaced by that of mCherry [64]. We excised most of the polylinker by 
digesting with BamHI + BglII, gel purifying, and religating, then PCR-
amplified the mCherry coding sequence plus the downstream SV40 
polyadenylation site with primers adding an outer EcoRI restriction site 
and an altered loxP site (loxP*) to each flank. The loxP* spacer region was 
GGATACTT rather than GCATACAT to make it incompatible with the loxP 
sites flanking the MuHV-4 BAC cassette. EGFP expression from an 
intergenic MuHV-4 M3 promoter (pM3-eGFP-pA) has been described [65]. 
We cloned the EcoRI-restricted loxP*-mCherry-pA-loxP* PCR product into 
the EcoRI site between the M3 promoter and the eGFP start codon of pM3-
eGFP-pA in pSP73. Genomic flanks for recombination were then added by 
blunt end cloning pM3-loxP*-mCherry-pA-loxP*-eGFP-pA into the MfeI site 
(genomic coordinate 77176) of a BglII genomic clone (75338-78717) in 
pSP73, then subcloning as a BglII fragment into the BamHI site of the 
KanR+SacB+orits shuttle vector pST76K-SR. pM3-loxP*-mCherry-pA-loxP*-
eGFP-pA was then recombined into the MuHV-4 BAC by transient RecA 
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expression, selection with kanamycin, and counter-selection with sucrose 
[62]. Recombinant clones were identified and checked for genomic 
integrity by restriction enzyme mapping. Infectious virus (mCherry+ from 
the reporter construct and eGFP+ from the BAC cassette) was recovered by 
transfecting BAC DNA into BHK-21 cells. This was then passed once 
through NIH-3T3-cre cells (infection at 2 p.f.u. / cell). Viruses excising the 
BAC cassette but retaining the complete loxP*-flanked reporter cassette 
(eGFP-mCherry+) were selected from the mixed progeny by flow 
cytometric sorting of infected cells and cloning on BHK-21 cells. Correct 
insertion of the expression cassette was confirmed by viral DNA 
sequencing. 
 Viruses were grown in BHK-21 cells by low multiplicity infection 
(0.01 p.f.u. / cell) and culture until >50% of cells showed cytopathic effects 
- typically 3-5 days. Viruses were grown in RAW-264 cells, which support 
lytic propagation less well, by infection at 0.1 p.f.u. / cell and culture for 2-
3 weeks, collecting the medium every 3-4 days and sub-culturing the cells 
as required. By this time >50% of the cells showed cytopathic effects. 
Virions were harvested from infected cell supernatants by 
ultracentrifugation (35,000 x g, 90 min). Cell debris was removed by low 
speed centrifugation (500 x g, 10min) and by filtration (0.45m). 
 
Plasmids  Expression constructs for the N-terminal 3 short 
consensus repeats of gp70 and the N-terminal 250 amino acids of gp150, 
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each fused to human IgG-Fc, have been described [37]. These were 
transfected into 293T cells using Fugene-6 (Roche Diagnostic Ltd). 
Recombinant proteins were collected from cell supernatants. The amounts 
of each Fc fusion were quantitated by immunoblotting for IgG-Fc and 
normalized on this basis. 
 
Virus assays Tissue blocks containing the whole upper respiratory 
tract epithelium [64] were homogenized in a pestle and mortar; lungs 
were homogenized mechanically (Omni International). Virus titers were 
then determined by plaque assay [24]. BHK-21 cell monolayers were 
incubated with virus dilutions (2h, 37°C), overlaid with 0.3% 
carboxymethylcellulose and 4 days later fixed with 4% formaldehyde and 
stained with 0.1% toluidine blue for plaque counting. Virus titers in 
spleens and lymph nodes were determined by infectious centre assay of 
single cell suspensions [24]. Tissue samples from mice infected with MHV-
RG were plated at limiting dilution and positive wells scored for red or 
green fluorescence under UV illumination. 
 Viral genome loads were measured by Q-PCR [64]. MuHV-4 genomic 
co-ordinates 4166-4252 (M2 gene) was amplified (Rotor Gene 3000, 
Corbett Research) from 50ng DNA extracted from ex vivo organs (Promega 
Corporation). The PCR products were quantitated by hybridization with a 
Taqman probe (genomic coordinates 4218-4189) and converted to 
genome copies by comparison with a standard curve of cloned plasmid 
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template, amplified in parallel. Cellular DNA was quantitated in the same 
reaction by amplifying part of the adenosine phosphoribosyl transferase 
(APRT) gene, again with Taqman probe hybridization and known template 
dilutions amplified in parallel for quantitation. Virus loads were then 
normalized by the cellular genome copy number of each sample. 
 
Flow cytometry Green (eGFP) and red (mCherry) fluorescence were 
measured directly. For antibody staining, adherent cells were plated 
overnight onto Petri dishes, then detached without trypsinization. Non-
adherent cells were used directly. B cells were identified by staining with a 
phycoerythrin-conjugated rat mAb to CD19 (BD Biosciences) or an 
Alexafluor633-conjugated pAb to mouse immunoglobulin (Invitrogen). 
Syndecan-1 and syndecan-4 were detected with phycoerythrin-conjugated 
mAbs (BD Biosciences); heparan sulfate was detected with mAbs F58-
10E4 and NAH46 (Seikagaku Corporation) plus Alexafluor488-conjugated 
pAb to mouse immunoglobulin (Invitrogen). Analysis was performed on a 
FACS Calibur and sorting on a FACS Vantage (BD Biosciences). 
 
Protein analysis  Virions were denatured by heating in Laemmli's 
buffer (50oC, 10min), then proteins resolved by SDS-PAGE and either 
stained with Coomassie Brilliant Blue followed by destaining in acetic acid 
/ methanol, or transferred to PVDF membranes. The membranes were 
blocked in 10% non-fat milk then incubated with mAbs specific for the gB 
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N-terminus (MG-2C10) [41], the C-terminal half of gB (MG-4D11) [43], 
gp70 (9C7) [33], gN (3F7) [66], gp150 (T1A1) [24] and thymidine kinase 
(CS-4A5) [67]. EGFP was detected with a rabbit pAb (Abcam). Antibody 
binding was detected with horseradish peroxidase-conjugated rabbit anti-
mouse IgG pAb or donkey anti-rabbit IgG pAb (Dako Corporation). 
Development was with ECL reagents (APBiotech) and exposure to X-ray 
film. 
 
Immunofluorescence  To analyse virion antigenicity, NMuMG 
cells were adhered to glass coverslips. Virions were then added to the cells 
at 4oC to allow binding but not endocytosis. The cells were then fixed (2% 
formaldehyde, 30min, 4oC) and blocked in PBS / 5% fetal calf serum / 
0.1% Tween-20. Pre-endocytic gB was detected with mAbs SC-9E8 or BN-
1A7 [45], post-endocytic gB with mAb MG-1A12 [43], gH/gL with mAb 
T2C12 [55], gL with mAb 47-5G10 [68] and gH-only with mAb MG-9B10 
[55]. In some experiments LAMP-1 was detected with mAb 104B (BD 
Biosciences). After the primary antibody incubations (1h, 23oC) the cells 
were washed x3 in PBS / 0.1% Tween-20, incubated with Alexafluor 568-
coupled goat anti-mouse-IgG pAb or with Alexafluor 488-coupled goat 
anti-mouse-IgG pAb + Alexafluor 568-coupled goat anti-rat IgG pAb (1h, 
23oC) (Invitrogen), washed x3 in PBS / 0.1% Tween-20, mounted in 
Prolong Gold with DAPI (Invitrogen), and imaged with an Olympus 
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microscope plus Hamamatsu digital camera or with a Leica SP2 confocal 
microscope. 
 
Immunohistochemistry  The anterior part of the skull containing 
the olfactory epithelium was removed post-mortem and fixed in 4% 
formaldehyde–PBS (4°C, 24h). Samples were decalcified in 250mM EDTA 
(two weeks, 23oC, changing the buffer every 2-3 days), then washed x2 in 
PBS and paraffin-embedded. 7μm sections were cut, de-paraffinised in 
xylene and rehydrated in ethanol / water. Antigen retrieval was 
performed by microwaving (850W, 5min) in 10mM NaCitrate pH 6 / 
0.05% Tween-20. Endogenous peroxidase activity was quenched in PBS / 
3% H2O2 for 10 min. The sections were then blocked with 2% rabbit serum 
and viral antigens detected with a MuHV-4-immune rabbit serum (18h, 
23oC) [27], biotinylated goat anti-rabbit IgG pAb and Vectastain Elite ABC 
Peroxidase system with ImmPACT DAB substrate (Vector Laboratories), 
washing x3 in PBS between each step. The sections were counterstained 
with Mayer’s Hemalum (Merck) and mounted in DPX (BDH). Viral 
miRNA/tRNAs 1-4 were detected by in situ hybridisation [28]. After de-
waxing in xylene and rehydration in ethanol / water, fixed sections were 
treated with proteinase K (100g/ml, 10min, 37oC) and acetylated with 
25% acetic anhydride in 0.1M triethanolamine. They were then hybridized 
in 50% formamide / 10mM Tris pH 7.5 with a digoxigenin-labelled 
riboprobe, generated by T7 transcription of pEH1.4 (58oC, 18h). 
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Hybridized probe was detected with alkaline phosphatase-conjugated 
anti-digoxigenin Fab fragments (Boehringer Ingelheim) and BCIP / NBT 
substrate. 
 For fluorescence imaging, samples were fixed in 1% formaldehyde / 
10mM sodium periodate / 75mM L-lysine (4oC, 24h), equilibrated in 30% 
sucrose (4oC, 18h), then frozen in OCT and sectioned (7m) on a cryostat. 
Sections were air dried (2h, 23oC) and blocked with 2% serum / 2% BSA / 
PBS (1h, 23oC). We detected macrophages with mAb F4/80 (Serotec) plus 
Alexafluor568-conjugated goat anti-rat IgG pAb (Invitrogen). We detected 
viral eGFP expression with rabbit anti-eGFP pAb (Abcam) plus 
Alexafluor488-conjugated goat anti-rabbit IgG pAb (Invitrogen). Sections 
were washed x3 in PBS after each antibody incubation (1h, 23oC), then 
mounted in Prolong Gold + DAPI (Invitrogen), visualised using a Leica TCS 
SP2 confocal microscope, and analysed with ImageJ. 
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Figure 1. Detection of MuHV-4 infection in the upper respiratory 
tract. 
a. C57BL/6 mice were infected with MuHV-4 (3x104 p.f.u. in 5l) and 6 
days later examined by immunostaining nasal sections with a MuHV-4-
specific polyclonal rabbit serum (brown). Arrowheads show examples of 
infected olfactory neuroepithelium. This and subsequent images are each 
representative of at least 3 mice examined. 
b. In contrast to the neuroepithelium, the nasal-associated lymphoid tissue 
(NALT) did not stain for viral antigens. 
c. Neuroepithelium on the same slide as the NALT in b stained strongly. 
d. Adjacent sections were assayed for viral miRNA/tRNA expression by in 
situ hybridization. Arrowheads show examples of infected olfactory 
neuroepithelium. 
e. No hybridization signal was observed in the NALT. 
f. Neuroepithelium on the same slide as the NALT was miRNA/tRNA+. 
g. At 14 days after virus inoculation (3x104 p.f.u. in 5l), NALT, superficial 
cervical lymph node (SCLN) and spleen sections were examined for viral 
miRNA/tRNA expression by in situ hybridization. All were positive. 
Arrowheads show examples of infected cells. 
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Figure 2. Infection of different cell types by gp150+ and gp150- MuHV-
4. 
a. HS+ and HS- CHO-K1 cells were exposed to gp150+ and gp150- versions 
of EF1-eGFP MuHV-4 for 18h. 20,000 cells were then assayed for viral 
eGFP expression by flow cytometry. Equivalent protein content of the 
gp150+ and gp150- virus stocks was confirmed by Coomassie staining 
(Fig.S2). 
b. RAW-264, NS0 and A20 cells were infected and analysed as in a. Bars 
show mean ± SD of 3 replicate experiments. Gp150- virions infected RAW-
264 and NS0 cells significantly better than did gp150+ virions (p<0.01 by 
Student's 2-tailed t test). 
 
Figure 3. Flow cytometric assay of cell surface HS expression. 
Cells were plated overnight onto Petri dishes, then detached without 
trypsin and stained with HS-specific mAbs (F58-10E4, NAH46) or with the 
HS binding N-terminal 3 SCR domains of the virion gp70 linked to human 
IgG-Fc. The N-terminal 250 amino acids of gp150 linked to IgG-Fc 
provided a negative control. Open histograms show specific staining; filled 
histograms show staining by secondary antibody alone. Equivalent data 
were obtained in a repeat experiment. 
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Figure 4. Binding of different cell types by gp150+ and gp150- virions. 
Cells were exposed to gp150+ and gp150- versions of MuHV-4 with eGFP 
linked to the cytoplasmic tail of gM (gM-eGFP) (4h, 37oC), then washed x3 
in PBS, and 20,000 cells assayed for virion binding / uptake by flow 
cytometry of eGFP fluorescence. Equivalent total protein content of the 
gp150+ and gp150- virus stocks was confirmed by Coomassie staining, and 
equivalent eGFP content was confirmed by immunoblotting (Fig.S3). 
Gp150 disruption significantly increased virus binding to all cell types 
(p<10-5 by Chi-squared test, comparing the relative proportions of eGFP+ 
and eGFP- cells over at least 3 virus dilutions). Similar data were obtained 
in a repeat experiment. 
 
Figure 5. Effect of syndecan-1 up-regulation on cell binding and 
infection. 
a. RAW-264 monocytes and A20 B cells were transduced or not with an 
uncleavable form of the HS carrier syndecan-1 (SDC-1). Flow cytometry 
confirmed syndecan-1 up-regulation; syndecan-4 staining is shown for 
comparison. HS expression was assayed by staining with the gp70 HS 
binding domains linked to IgG-Fc (gp70-SCR1-3-Fc). Open histograms 
show specific staining; closed histograms show staining by secondary 
antibody alone. Equivalent data were obtained in a repeat experiment. 
b. Cells were exposed to gp150+ and gp150- versions of MuHV-4 with eGFP 
linked to the cytoplasmic tail of gM (gM-eGFP) (4h, 37oC). After washing x3 
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in PBS, 20,000 cells were assayed for viral eGFP uptake by flow cytometry. 
Bars show mean ± SEM of 3 replicate experiments. 0 = no virus. SDC-1 
expression significantly increased gp150+ virion binding to A20 cells and 
gp150- virion binding to both A20 and RAW-264 cells (p<0.01 by Student's 
t test for at least 2 virus dilutions). 
c. Cells were exposed to wild-type (gp150+) or gp150- versions of EF1-
eGFP MuHV-4 (18h, 37oC). 20,000 cells were then assayed for viral eGFP 
expression by flow cytometry. Bars show mean ± SEM of 2 replicate 
experiments. 0 = no virus. SDC-1 expression significantly increased RAW-
264 cell infection by gp150+ and gp150- viruses (p<0.01 by Student's t test 
for at least 2 virus dilutions) but not A20 cell infection. 
 
Figure 6. Infection by co-culture. 
a. BHK-21 cells were infected with gp150+ or gp150- EF1-eGFP MuHV-4 
at different multiplicities (2h, 37oC), then washed x3 in PBS and cultured 
overnight with an equal number of RAW-264 cells. 18h later RAW-264 
cells (CD11b+) eGFP expression was assayed by flow cytometry. Each point 
shows the mean ± SD of 3 replicate cultures. Equivalent data were 
obtained in 3 experiments. 
b. Gp150+ or gp150- EF1-eGFP MuHV-4 (106 p.f.u.) was added to 3x105 
RAW-264 cells or BHK-21 cells. 18h later 106 spleen cells were added to 
these cultures. As a control, a further 106 spleen B cells were exposed 
directly to 106 p.f.u. of virus. 24h later eGFP expression in B cells (CD19+) 
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was assayed by flow cytometry. The numbers show mean ± SD %eGFP+ of 
total CD19+ cells in 5 experiments. All BHK-21 cells and most RAW-264 
cells were excluded from the flow cytometric analysis by FSC / SSC gating. 
The CD19-eGFP+ cells in RAW-264 cell co-cultures correspond to residual 
infected RAW-264 cells. The splenocytes included very few myeloid cells 
(<1% CD11bhi or CD11c+). 
c. Gp150+ or gp150- EF1-eGFP MuHV-4 (106 p.f.u.) was added to 106 
peritoneal macrophages. 3 days later, to allow for the limited lytic 
infection of these cells, we added 106 spleen cells. 18h later eGFP 
expression in B cells (CD19+) was assayed by flow cytometry. The 
numbers show the % cells in each quadrant. All CD19-eGFP+ cells were 
CD11bhi macrophages. Again control BHK-21 cell co-cultures gave <0.5% 
eGFP+ B cells. Equivalent data were obtained in 3 experiments. 
d. A MuHV-4 recombinant (MHV-RG) was generated in which a viral M3 
promoter (pM3) drives mCherry expression from the ORF57 / ORF58 
intergenic site. LoxP recombination by cre excises mCherry plus its 
polyadenylation signal to release eGFP expression from the same 
promoter. 
e. Cre+ or control cre- NIH-3T3 cells were infected or not with MHV-RG 
(0.5 p.f.u. / cell) and 18h later imaged for red (mCherry) and green (eGFP) 
fluorescence. Nuclei were counterstained with DAPI. 
f. BHK-21 cells or RAW-264 cells were infected with MHV-RG (1 p.f.u. / 
cell, 18h) then co-cultured with cre+ NS0 cells. After 3 days the NS0 cells 
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(MHC class IIhi) were analysed for green and red fluorescence by flow 
cytometry. The percentage of total cells in each gate is indicated. 
Equivalent data were obtained in a repeat experiment. 
 
Figure 7. B cell infection by virions derived from RAW-264 cells. 
a. Gp150+ and gp150- EF1-eGFP virions were grown in BHK-21 
fibroblasts or RAW-264 monocytes, then added (3 p.f.u. / cell, 18h) to 
spleen cells. An example flow cytometric plot of eGFP expression in CD19+ 
B cells is shown. Data from replicate experiments are summarized in b. 
b. Gp150+ or gp150- EF1-eGFP virions, propagated in BHK-21 or RAW-
264 cells were added to BHK-21 cells or spleen cells at different 
multiplicities. 18h later cells were scored as eGFP+ or eGFP- by flow 
cytometry. Each point shows mean ± SD of 5 experiments. 
c. Gp150+ or gp150- EF1-eGFP virions from BHK-21 cells or RAW-264 
cells were added to BHK-21 cells (0.5 p.f.u. / cell) or to spleen cells (3 p.f.u. 
/ cell). After 4h at 37oC, residual input virus was inactivated by acid wash. 
The cells were then split for analysis of recoverable infectivity by 
infectious centre assay, virus binding by Q-PCR of viral (M2) versus 
cellular (APRT) genome load and after further culture (16h, 37oC) for flow 
cytometric assay of eGFP expression. Each bar shows mean ± SEM of 
triplicate cultures. Equivalent data were obtained in a repeat experiment. 
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Figure 8. Glycoprotein analysis of MuHV-4 propagated in RAW-264 
cells. 
a. EF1-eGFP virions propagated in BHK-21 (BHK) or RAW-264 (RAW) 
cells were assayed for virion components by immunoblotting. gB (C) and 
gB (N) are the C-terminal and N-terminal halves of gB after its cleavage by 
furin. The upper band corresponds to uncleaved gB. 
b. Wild-type MuHV-4 virions propagated in BHK-21 cells were bound to 
NMuMG cell monolayers (3h, 4oC, 3 p.f.u. / cell), then washed x2 in PBS 
and either fixed immediately, or incubated further (2h, 37oC) before 
fixation to allow virion endocytosis. The cells were then analysed by 
immunofluorescence for virion antigen display. 
c. EF1-eGFP virions propagated in BHK-21 or RAW-264 cells were bound 
to NMuMG cell monolayers (3h, 4oC, 25 eGFP units / cell - equivalent to 3 
p.f.u. / cell), then washed x2 in PBS, fixed and analysed by 
immunofluorescence for virion antigen display. Each dot corresponds to a 
positive virion. The numbers show mean ± SD positive virions per cell for 
25 cells per sample. Comparison by Student's t test showed that 
significantly more RAW-264-derived virions than BHK-21 cell-derived 
virions were recognized by mAbs MG-1A12 and MG-9B10, and 
significantly fewer by mAbs T2C12 and 47-5G10 (p<0.01). Equivalent data 
were obtained in 2 further experiments. 
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Figure 9. Tracking myeloid infection in vivo. 
a. C57BL/6 mice were infected i.n. with EF1-eGFP+ MuHV-4 (3x104 p.f.u. 
in 5l) and 1 day later analysed by immunofluorescent staining of the 
neuroepithelium for viral eGFP (green) and for macrophages with mAb 
F4/80 (red). The image shows a single infected epithelial cell - that is 
before substantial virus spread - contacting a macrophage. 
b. Mice were infected as in a, then analysed 1 day later for viral lytic 
antigen expression with an immune rabbit serum (green) and for 
macrophage distribution with mAb F4/80 (red). The arrowhead in the 
zoomed merge shows lytic antigens in an F4/80+ cell (yellow). 
c. Cre transgenic mice were infected i.n. with MHV-RG (3x104 p.f.u. in 5l), 
and the recovered virus analysed for cre-mediated switching from red 
(eGFP-mCherry+) to green fluorescence (eGFP+mCherry-). Each point 
shows the % eGFP+mCherry- of total plaques. Round points show 
individual mice, square points show means. Virus was recovered from 
noses by plaque assay at days 3, 5 and 8 post-infection for lysM-cre mice 
and at days 3 and 8 for CD19-cre mice. CD11c-cre mice were not analysed. 
Virus was recovered from the draining superficial cervical lymph nodes 
(SCLN), by infectious center assay at days 8 and 15 post-infection for lysM-
cre and CD19-cre mice, and at day 15 for CD11c-cre mice. Plaques and 
infectious centers from non-transgenic C57BL/6 mice were 100% eGFP-
mCherry+. 
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